Daily Briefing – June 12: PPI confirms pipeline inflation shock, oil slides on U.S.-Iran deal hopes, ECB turns hawkish, SpaceX debut tests risk appetite

The June 12, 2026 briefing shifts from pure fear to a more tradable but still fragile tape. Yesterday’s official PPI release confirmed that the inflation problem is not only consumer-facing: final demand producer prices rose 1.1% in May, goods prices jumped 2.8%, and final demand less foods, energy and trade services rose 0.8%, with the 12-month core measure at 5.1%. The good news for risk assets is that oil is finally giving the market some oxygen: Brent fell back toward the high-$80s after President Trump called off planned strikes on Iran and said talks had progressed, although Tehran has not confirmed a final deal and the Strait of Hormuz risk remains unresolved. Europe is also back in the spotlight after the ECB raised rates, with the deposit facility moving to 2.25% from June 17 and officials keeping a July move on the table if inflation does not cool. The equity read is clearer than yesterday: AI remains structural, but Oracle’s capex-heavy cloud story has made investors more selective, while the SpaceX market debut is now the biggest sentiment test for speculative growth, retail risk appetite and the wider space-stock complex.

• SPCX— SpaceX is the headline risk-appetite event as its Nasdaq debut follows a record IPO and a reported valuation near $1.77T. For traders, the first session is not just about one company: it is a live test of retail demand, mega-growth valuation tolerance and the appetite for space-linked equities.Space IPO
• RKLB / LUNR / PL / SATL— Public space names remain the read-through basket around SpaceX. A strong debut can lift sentiment across launch, lunar infrastructure, Earth observation and satellite communications, but a weak debut would quickly remind traders that “space” is still a high-volatility theme.Space Basket
• ORCL— Oracle remains the key post-earnings AI capex lesson. The company reported Q4 revenue of $19.2B, cloud revenue of $9.9B and RPO of $638B, but fiscal-year free cash flow was negative $23.7B as cloud infrastructure investment absorbed the story.AI Capex
• NVDA— Nvidia is still the anchor of the AI trade, but the market is no longer treating every AI infrastructure headline as automatically bullish. The tape is moving toward a sharper distinction between companies selling the picks and shovels and companies carrying the funding burden.AI Leader
• AVGO / MRVL— Broadcom and Marvell remain important custom-silicon and AI-networking reads. Marvell also keeps its S&P 500 inclusion angle before the June 22 open, which adds passive-flow demand to the fundamental AI discussion.AI Semis
• FLEX— Flex remains in focus ahead of S&P 500 inclusion before the June 22 open. The setup is less about one daily headline and more about benchmark demand, positioning and technology supply-chain exposure.Index Flow
• AAPL— Apple stays under the consumer-AI and EU regulatory lens after the company said DMA-related issues would delay Siri AI features for iOS 27 and iPadOS 27 users in the European Union. The stock remains a key test of mega-cap quality versus AI execution friction.AI / EU
• NVO / LLY— Novo Nordisk is back in the GLP-1 spotlight after UK approval of its oral semaglutide weight-loss pill, the first European market opening for the tablet version. Lilly remains the direct competitive benchmark after its U.S. oral obesity-pill approval earlier this year.Obesity Drugs
• May PPI— The official BLS report showed final demand PPI up 1.1% in May and 6.5% over 12 months, with energy-heavy goods doing most of the damage. This keeps inflation pressure alive even as oil eases today.Macro / PPI
• May CPI— CPI remains the background pressure after the BLS confirmed a +4.2% year-over-year May reading and +2.9% core CPI earlier this week. The combination of CPI and PPI keeps the Fed relief trade fragile.Macro / CPI
• VRDN— Viridian remains one of the cleaner near-term biotech catalyst watches, with veligrotug under Priority Review and a June 30, 2026 PDUFA target date in thyroid eye disease.PDUFA Watch
• GILD / MRK— Gilead and Merck remain relevant after positive Phase 3 topline data for the once-weekly oral HIV combination islatravir/lenacapavir. Long-acting and lower-burden chronic-disease treatment remains one of pharma’s stronger durable themes.HIV / Phase 3
• COGT / BBIO / VERA / CORT / CAPR— The FDA/catalyst basket remains central in a selective biotech tape. Traders need to read catalyst timing together with cash runway, label risk, dilution risk and the quality of the clinical/regulatory setup.Biotech FDA
• Ponte Messina (Italy)— The Sicily-mainland bridge corruption probe remains an Italian political and infrastructure story to monitor. It is not a direct U.S. market catalyst, but it still matters for domestic political risk and large-project governance sentiment.Italy / Politics

• PPI shock— May PPI confirmed that upstream inflation is hot: final demand +1.1%, goods +2.8%, energy +10.7%, and core final demand less foods, energy and trade +0.8%. That is why the market can rally on lower oil but cannot ignore rates.Inflation
• Oil relief— Brent fell back toward the high-$80s after Trump called off planned Iran strikes and talked up progress toward a deal. The market is breathing, but this is relief, not resolution: Hormuz risk has not disappeared.Oil / Geo
• U.S.-Iran diplomacy— The geopolitical trade is now binary again. A credible deal would support travel, airlines, consumer discretionary and growth multiples; a failed deal would quickly put oil, defense and inflation hedges back in control.Geopolitics
• ECB hike— The ECB’s deposit facility is moving to 2.25% from June 17, with main refinancing operations at 2.40% and marginal lending at 2.65%. Europe is now explicitly reacting to war-driven inflation rather than waiting for it to fade.Europe / ECB
• Rates still matter— Lower oil helps, but CPI and PPI make it hard for the Fed or ECB to sound dovish. That matters most for QQQ, SOXX, IWM, XBI and any small-cap story that still depends on external capital.Rates
• Global risk tone— Europe and Asia rallied on peace hopes while Wall Street futures looked more cautious. The setup is constructive, but the market still wants confirmation from oil, semis, credit spreads and the SpaceX debut.Risk Appetite
• AI capex filter— Oracle changed the AI conversation. Backlog and cloud growth still matter, but investors are now asking how much debt, capex and negative free cash flow are needed to buy that growth.AI Valuation
• Travel and leisure— Lower oil and Gulf peace hopes support airlines, travel and consumer services. The World Cup opening week also keeps media, payments, travel and advertising narratives active, even if it is not a single-stock catalyst by itself.Travel / Media
• Biotech selectivity— A better risk tape helps XBI, but hot PPI and high rates still punish weak balance sheets. The group remains catalyst-driven: clean data, credible FDA paths and enough cash matter more than broad sector hype.Biotech
• Credit check— Credit spreads and high-yield tone are important today. If credit stays calm while oil falls, the rally has better legs; if spreads widen again, small caps and speculative growth will likely lag.Credit